SCHEMBL3004091

SCHEMBL3004091

Cc1cc(C)c(C)c(S(=O)(=O)N2CCN(c3nc(Cc4ccc(Cl)cc4Cl)cs3)CC2)c1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
GAA P10253 3/20 0.43
LMNA P02545 3/20 0.43
HTT P42858 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
MAPT P10636 2/20 0.43
ALDH1A1 P00352 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
FPR2 P25090 2/20 0.39
PROKR1 Q8TCW9 2/20 0.39
EPHX2 P34913 2/20 0.39
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
POLB P06746 2/20 0.38
MAPK1 P28482 2/20 0.38
AR P10275 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3648733 0.94 HTT (0.39) MEN1KMT2AGAALMNAHTT
SCHEMBL3014554 0.90 EPHX2 (0.49) MEN1KMT2AGAAHTTALDH1A1
SCHEMBL2999817 0.89 MEN1 (0.44) MEN1KMT2AGAALMNAHTT
SCHEMBL3015848 0.86 SMN1; SMN2 (0.41) MEN1KMT2AGAALMNAL3MBTL1
SCHEMBL3017014 0.86 MEN1 (0.45) MEN1KMT2AGAALMNAHTT
SCHEMBL3014339 0.86 KMT2A (0.43) MEN1KMT2AGAALMNAHTT
SCHEMBL3019215 0.86 GAA (0.36) GAALMNAHTTL3MBTL1MAPT
SCHEMBL3017406 0.85 EPHX2 (0.44) MEN1KMT2AGAALMNAMAPT
SCHEMBL3017007 0.85 L3MBTL1 (0.44) MEN1KMT2AGAALMNAHTT
SCHEMBL2997910 0.85 MEN1 (0.44) MEN1KMT2AGAALMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MEN1 454/4885KMT2A 2680/4885GAA 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.